8-K: Bio-Techne Reports Mixed Q3 Results Amidst Market Headwinds, Declares Dividend

Bio-Techne reported a 3% increase in third-quarter revenue, with a 2% organic growth, alongside a decrease in GAAP and adjusted EPS, while also announcing a cash dividend of $0.08 per share.

Summary

• Bio-Techne's third-quarter fiscal year 2024 revenue reached $303.4 million, a 3% increase compared to the same period last year.
• Organic revenue growth was 2%, with acquisitions contributing 1%.
• GAAP earnings per share (EPS) decreased to $0.31 from $0.43 year-over-year.
• Adjusted EPS was $0.48, down from $0.53 in the prior year.
• The Diagnostics & Genomics segment showed strong growth with a 10% organic revenue increase.
• Cash flow from operations increased by 31% to $223.5 million.
• The company declared a cash dividend of $0.08 per share, payable on May 24, 2024, to shareholders of record on May 13, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While there are positives like revenue growth and strong cash flow, the decrease in EPS and operating income, along with margin pressures, temper the overall outlook.

Positives

• The company achieved solid top-line performance despite challenging market conditions.
• There was a 290 basis-point sequential improvement in adjusted operating margin.
• The Diagnostics & Genomics segment showed strong organic growth of 10%.
• Cash flow from operations increased significantly by 31% year-over-year.
• The company's cell and gene therapy workflow solutions saw continued uptake, with record sales for the GMP reagent portfolio.

Negatives

• GAAP EPS decreased to $0.31 from $0.43 year-over-year.
• Adjusted EPS decreased to $0.48 from $0.53 in the prior year.
• GAAP operating income decreased by 16% to $67.0 million.
• Adjusted operating income decreased by 8% to $99.6 million.
• The Protein Sciences segment experienced a 2% decrease in net sales.
• The Diagnostics and Genomics segment operating margin decreased to 9.3% from 15.2% due to the Lunaphore acquisition.

Risks

• The company is facing headwinds from a depressed biopharma end market.
• The Protein Sciences segment experienced a decrease in sales and operating margin due to unfavorable volume leverage and product mix.
• The Diagnostics and Genomics segment's operating margin was negatively impacted by the Lunaphore acquisition.
• The company's results are subject to risks related to new branding and marketing initiatives, integration of new businesses, and the introduction of new products.
• General economic conditions, customer site closures, and supply chain issues could also affect future results.

Future Outlook

The company's forward-looking statements include potential future repurchases of Bio-Techne common stock, but are subject to various risks and uncertainties.

Management Comments

• Kim Kelderman, President and Chief Executive Officer of Bio-Techne, stated that he is proud of the team's execution under challenging market conditions.
• Kelderman noted that the company experienced subsiding headwinds from de-stocking and delivered year-over-year growth in a depressed biopharma end market.
• Kelderman highlighted the company's differentiated portfolio and its position to catalyze advances in science and medicine.

Industry Context

Bio-Techne operates in the competitive life sciences industry, facing challenges such as price competition and the impact of economic conditions on research funding. The company's focus on cell and gene therapy solutions aligns with growing trends in the biopharma sector.

Comparison to Industry Standards

• While Bio-Techne's Diagnostics & Genomics segment showed strong growth, the Protein Sciences segment's decline contrasts with some competitors who have seen more stable growth in core research products.
• The decrease in GAAP and adjusted EPS is a concern, as many companies in the sector are focused on improving profitability.
• The 31% increase in cash flow from operations is a positive sign, outperforming some peers who have struggled with cash generation.
• The adjusted operating margin of 33.0% is competitive, but the decrease from 37.0% in the prior year indicates some challenges in maintaining profitability.
• Companies like Thermo Fisher Scientific and Danaher, which are also in the life sciences space, have reported varying results, with some showing stronger growth in certain segments and others facing similar margin pressures.

Stakeholder Impact

• Shareholders will receive a dividend of $0.08 per share.
• Employees may be impacted by restructuring and efficiency initiatives.
• Customers will benefit from the company's continued innovation in life sciences tools and reagents.
• Suppliers may see changes in demand based on the company's performance in different segments.

Next Steps

• The company will host an earnings conference call on May 1, 2024, to discuss the results.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Keywords

Bio-Techne, biotechnology, life sciences, diagnostics, genomics, reagents, cell therapy, gene therapy, EPS, revenue, dividend, operating margin